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Intracellular tau aggregates are the neuropathological hallmark of several neurodegenerative diseases, including Alzheimer’s disease,
progressive supranuclear palsy, and cases of frontotemporal dementia, but the link between these aggregates and neurodegeneration
remains unclear. Neuronal models recapitulating the main features of tau pathology are necessary to investigate the molecular mecha-
nisms of tau malfunction, but current models show little and inconsistent spontaneous tau aggregation. We show that dorsal root
ganglion (DRG) neurons in transgenic mice expressing human P301S tau (P301S-htau) develop tau pathology similar to that found in
brain and spinal cord and a significant reduction in mechanosensation occurs before detectable fibrillar tau formation. DRG neuronal
cultures established from adult P301S-htau mice at different ages retained the pattern of aberrant tau found in vivo. Moreover, htau
became progressively hyperphosphorylated over 2 months in vitro beginning with nonsymptomatic neurons, while hyperphosphory-
lated P301S-htau-positive neurons from 5-month-oldmice cultured for 2months died preferentially. P301S-htau-positive neurons grew
aberrant axons, including spheroids, typically found in human tauopathies. Neurons cultured at advanced stages of tau pathology
showed a 60%decrease in the fraction ofmovingmitochondria. SEG28019, a novel O-GlcNAcase inhibitor, reduced steady-state pSer396/
pSer404 phosphorylation over 7weeks in a significant proportion of DRGneurons showing for the first time the possible beneficial effect
of prolonged dosing of O-GlcNAcase inhibitor in vitro. Our system is unique in that fibrillar tau formswithout externalmanipulation and
provides an important new tool for understanding themechanisms of tau dysfunction and for screening of compounds for treatment of
tauopathies.
Introduction
Insoluble aggregates made of microtubule-associated protein tau
represent the pathological hallmark of several neurodegenerative
diseases, including Alzheimer’s disease, Pick’s disease, progressive
supranuclear palsy, corticobasal degeneration, and frontotemporal
dementiawithparkinsonism linked to chromosome17 (FTDP-17T;
Goedert et al., 2012; Spillantini and Goedert, 2013). Tau is a soluble
phospho-protein that is expressed in neurons of the CNS and pe-
ripheral nervous system (PNS), where it is found mainly in axons
(Cleveland et al., 1977; Binder et al., 1985). Tau is implicated in the
assembly and stabilization ofmicrotubules (MTs), as well as in neu-
ritogenesis, axonal maintenance, and transport (Morris et al., 2011;
MandelkowandMandelkow,2012).The identificationofmutations
in the tau gene MAPT in cases of FTDP-17T demonstrated the rel-
evance of tau for neurodegeneration (Hutton et al., 1998; Poorkaj et
al., 1998; Spillantini et al., 1998) and led to the development of cell
and animal models of tau pathology.
While several transgenicmodels have been created that repro-
duce features of tau pathology and tau-related cell death, cellular
models with consistent and reproducible filamentous tau aggre-
gates are not available. Cells that reproduce the key hallmarks of
tau pathology would provide a means of studying the as yet un-
clear basic mechanisms associated with tau pathophysiology and
toxicity, and would be an important tool for screening potential
therapeutic compounds.
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To establish cultures of primary neurons that would recapit-
ulate the main features of tau dysfunction in a cell-autonomous
manner, we focused on neurons from dorsal root ganglia (DRG)
of transgenic mice expressing human P301S tau under the con-
trol of the Thy1.2 promoter (Allen et al., 2002). In a homozygous
state these mice develop a stereotypic tauopathy that culminates
in severe neurodegeneration at5–6 months of age. DRG neu-
rons constitute an ideal cellularmodel, since they can be cultured
from adult mice formonths, potentially enabling the progression
of pathological features to develop in a time-dependent manner.
Furthermore,DRGneurons are relevant as amodel of tau pathol-
ogy, because filamentous tau has been reported in lumbar DRG
neurons from progressive supranuclear palsy (PSP) patients
(Nishimura et al., 1993), as well as in other peripheral ganglia in
Alzheimer’s disease (AD; Kawasaki et al., 1987).
Here we show that tau pathology progresses spontaneously in
cultures of DRG neurons from adult P301S-htau mice. We dem-
onstrate that the presence of pathological tau in P301S-htauDRG
neurons is associated in vivo with a reduction in mechanosensa-
tion. Moreover, DRG neuronal cultures from P301S-htau mice
develop age-dependent tau pathology similar to CNS neurons in
vivo, morphological alterations in axons similar to those de-
scribed in human tauopathies, and time-dependent alterations in
mitochondrial axonal transport. Furthermore, tau hyper-
phosphorylation develops progressively in DRG neurons kept
in culture for 8 weeks. We demonstrate the model’s utility for
drug screening using a novel potent and selective iminosugar
O-GlcNAcase inhibitor (Hart et al., 2011; Horne et al., 2011)
and show a reduction in phosphorylation of tau at pSer396/
pSer404, the PHF-1 epitope. Our data show that P301S-
htauve DRG neurons are a valuable model to investigate tau
pathology and potential treatments.
Materials andMethods
Antibodies. Anti-phospho-tau AT8 (epitope pS202/pT205), AT100
(epitope pT212/pS214), AT180 (epitope pT231), and anti-human tau
HT7 (epitope 159–163) mouse monoclonal antibodies (Biernat et al.,
1992; Goedert et al., 1995; Yoshida and Goedert, 2006) were from Inno-
genetics NV or Thermo Scientific. PHF-1 (epitope pS396/pS404) and
MC1 (conformational antibody; Jicha et al., 1997; Weaver et al., 2000;
Jeganathan et al., 2008) (mousemonoclonals) were a kind gift fromDr. P
Davies, Albert Einstein College ofMedicine, NewYork. Other antibodies
include rabbit polyclonal anti-Tau (A0024, Dako), rabbit polyclonalIII
tubulin (Covance; PRB-435P-100), Anti-O-GlcNAc antibody RL2
(ab2739; Abcam), anti-Tau C terminus BR134 (Spillantini et al., 1996;
Allen et al., 2002), and isolectin IB4 conjugated to FITCwas fromVector
Laboratories. All the primary antibodies used for DRG immunolabeling
were used at 1:500–1000 with the exceptions of RL2, which was used at
1:300, and IB4-FITC used at 1:100. All secondary antibodies were used at
1:1000 for immunocytochemistry and 1:5000–10,000 for immunoblotting.
Animals. Homozygous P301S-htau mice (Allen et al., 2002) and
C57BL/6S (C57BL/6 OlaHsd; Harlan) control mice were maintained on
a 12 h light/dark cycle in a temperature-controlled room (22°C) in cages
with free access to food and water. No difference was observed in DRG
cultures from male and female P301S-htau mice, therefore, both male
and female mice were used in the study. All procedures were performed
in accordance with the UK Animal (Scientific Procedures) Act 1986 for
the welfare of laboratory animals and were approved by the Cambridge
University local ethical committee.
Dissociated adult mouse DRG cultures. Protocols for culturing dissoci-
ated DRG neurons from adult mice were adapted fromMalin et al., 2007
and Gumy et al., 2008. Briefly, mice were killed by CO2 inhalation fol-
lowed by cervical dislocation and the total pool of DRGs per mouse was
collected in L15 medium (Life Technologies). Meninges and roots were
removed and ganglia were digested with 2 mg/ml collagenase (Sigma-
Aldrich) at 37°C for 1 h followed by addition of 0.1% trypsin (Sigma-
Aldrich) for 10 min. DRGs were collected into DMEM (Life
Technologies) containing 9% fetal bovine serum (FBS; Life Technolo-
gies), triturated into a homogenous cell suspension, and centrifuged at
1000  g for 2 min. The cell pellet was resuspended in culture medium
(DMEMsupplementedwith 1%FBS, penicillin-streptomycin-fungizone
PSF; Life Technologies) and 20 ng/ml NGF (Sigma-Aldrich). For long-
term cultures, Neurobasal A medium (Life Technologies) containing
B27 (Life Technologies), Glutamax (Life Technologies), PSF, NGF, and a
mixture of 20 M 5-fluoro-2-deoxyuridine/uridine and 0.5 g/ml mi-
tomycin C (Sigma-Aldrich) was used. DRG cells were plated onto poly-
D-lysine and laminin-coated glass coverslips or glass-bottomed dishes
(MatTek). Cells were grown at 37°C in 7% CO2 and the medium was
changed twice a week. Each culture was obtained using the whole DRG
set from a single mouse. For SEG28019 testing, DRG neurons were cul-
tured from 3-month-old P301S-htau mice. SEG28019 (Summit plc; 20
mg)was dissolved in 100l of dimethylsulfoxide, andwaterwas added to
make a 30 mM stock solution. Aliquots were kept at 20°C. SEG28019
was freshly diluted into long-term culture medium to a final concentra-
tion of 10 M just before addition to the neurons. Medium containing
SEG28019 was first added after 2 days in vitro (DIV), and half the volume
of media of both untreated and treated cultures was changed twice a
week.
Immunocytochemistry. DRG cultures were fixed in 4% paraformalde-
hyde (PFA) for 15 min at room temperature, washed in PBS, permeabil-
ized, and blocked in PBS/0.01% Triton X-100 (PBST) containing 5%
serum of the appropriate species, or in PBS/0.3% Triton X-100 without
blocking, and incubated with primary antibodies in PBST overnight at
4°C. Secondary antibodies conjugated with Alexa fluorochromes (Life
Technologies) were incubated for 1 h at room temperature and nuclei
stained with 1 g/ml Hoechst 33258 (Sigma-Aldrich). Cultures were
mounted in FluorSave (MerckMillipoe). For dual labeling of dissociated
DRG cultures with the monoclonal antibodies PHF-1/AT8/AT100 and
HT7, incubations were performed sequentially in two rounds: cells were
incubated with the anti-phospho-tau antibody together with the anti-
III tubulin antibody followed by the appropriate secondary antibodies,
then withHT7 followed by a secondary antibody that showed no spectral
overlap. For DRG sections, mice were anesthetized by intraperitoneal
injection of sodium pentobarbital (Euthatal; 2 ml/kg; Rhoˆne-Me´rieux),
and perfused transcardially with PBS followed by 4% PFA (Sigma-
Aldrich) in 0.1 M phosphate buffer, pH 7.4. DRGs were postfixed in 4%
PFA for 30 min at 4°C, washed, and cryopreserved in PBS/15% sucrose
containing 0.02% sodium azide at 4°C. Tissue was embedded in OCT
mounting medium (Thermo Scientific), frozen in cold 2-methylbutane
for 5 min, and sectioned using a Leica CM 3050S cryostat. Cryostat
sections (12 m) were mounted onto poly-L-lysine-coated glass slides
(SuperFrost Plus; VWR), stained, and then coverslipped in FluorSave.
Labeling was visualized using a Leica TMDM 6000B fluorescence micro-
scope and images were acquired with Leica LAS AF software.
Quantification of P301S-htau expression and phosphorylation.The total
number of neurons in nine fields (20 objective; 200–400 neurons;
Leica DM6000 microscope) was counted per coverslip per culture, and
the percentage of P301S-htauve out of III tubulinve neurons, or
phosphorylated P301S-htauve out of total P301S-htauve neurons was
calculated. Significance was determined by one-way ANOVA adjusted
with Bonferroni post hoc adjustment. For analysis of PHF-1 expression in
SEG28019-treated neurons, the intensity of labeling of PHF-1 was mea-
sured and normalized to that of HT7, after confirmation that intensities
were in the linear range. All the positive neurons on the coverslip were
scored. Because the data did not follow a normal distribution, the non-
parametric Mann–Whitney test was applied to determine significance
and p values.
Axon length and growth cone area quantification. Low-density dissoci-
ated DRG cultures from P301S-htau and C57BL/6S mice of various ages
were grown for 2 DIV and costained with anti-III tubulin and anti-tau
HT7 antibodies. Images of dissociatedDRGneuronswere acquired using
a LeicaDM6000microscope. The length of the longest axonal process per
neuron and the area of the associated growth cone (70–90 neurons each
of HT7ve, HT7ve in P301S-htau and C57BL/6S wild-type mice per
independent culture) were determined with ImageJ software (National
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Institutes of Health; http://rsbweb.nih.gov/ij/index.html). The drawing
tool was used to trace and measure the length of the longest neurite per
cell from the axon hillock to the growth cone. The samemethodwas used
to trace around the growth cone to obtain the area and perimeter in
micrometers. Three and four independent DRG cultures from, respec-
tively, control and transgenic animals at each age were analyzed. Signif-
icance was tested by two-way ANOVA followed by Bonferroni post hoc
adjustment.
Protein extraction.DRGs, spinal cord, and brain (cortex or brainstem)
were dissected from a 5-month-old mouse and immediately frozen on
dry ice. For soluble tau extraction, DRGs from four P301S-htau mice
were pooled. For sarkosyl-insoluble preparations, DRGs were pooled
from five P301S-htau and five control mice. For sarkosyl-insoluble prep-
arations from 2 DIV cultures, DRGs were from a single 5-month-old
P301S-htau or control mouse. Soluble tau was extracted essentially as
previously described (Goedert and Jakes, 1990). Briefly, tissue was ho-
mogenized in 2.5% (v/v) perchloric acid (0.5 ml/200 mg; Sigma-
Aldrich), centrifuged at 12,000 g for 10min at 4°C, and the supernatant
dialyzed against 50 mM Tris-HCl, pH 7.4, 0.1 mM EDTA and 1 mM phe-
nylmethylsulfonyl fluoride (Sigma-Aldrich) overnight at 4°C. Half of the
sample was dephosphorylated with 18 U/ml Escherichia coli alkaline
phosphatase (AP) (Promega) in 50 mM Tris-HCl, pH 7.4, containing 5
mM MgCl2 for 3–4 h at 65°C. Sarkosyl-insoluble tau extraction was per-
formed as previously reported (Allen et al., 2002), samples were homog-
enized in A68 buffer (10 mM Tris-HCl, pH 7.4, 0.8 M NaCl, 1 mM EGTA,
and 10% sucrose). The homogenate was centrifuged at 15,000 g for 20
min at 4°C and the supernatant was collected, while the pellet was resus-
pended in A68 buffer and recentrifuged. The supernatants were com-
bined and incubated in 1% sarkosyl (Sigma-Aldrich) containing
cOmplete protease inhibitor cocktail (Roche) for 1 h at room tempera-
ture and centrifuged at 100,000 g for 1 h at 4°C (Optima MAX Ultra-
centrifuge; Beckman Coulter). The pellet was reconstituted in 50 mM
Tris-HCl, pH 7.4, and used for immunoblotting. The same protocol was
used for extraction of insoluble tau from tissue and DRG cultures except
that the cells were collected and homogenized directly in A68 containing
1% sarkosyl and protease/phosphatase (Sigma-Aldrich) inhibitors. After
spinning at 100,000 g for 1 h at 4°C, the pellet was rinsed once in the
samebuffer, reconstituted in sample buffer, andhalf of the aliquot loaded
on the gel.
Immunoblotting. Proteins were solubilized in gel-loading buffer, re-
solved on 10% SDS-PAGE, and transferred onto PVDF membranes
(Merck). Nonspecific background was blocked in 5% w/v Marvel milk
(Premier International Foods) in TBS-T and incubated with the primary
antibody overnight at 4°C, followed by 1 h at room temperature in the
appropriate peroxidase-labeled secondary antibody. Blots were devel-
oped with ECL Plus (GE Healthcare). Each experiment was repeated
three times using independent sets of samples.
Immunogold electron microscopy. Sarkosyl-insoluble proteins were ex-
tracted from DRG tissue or cell pellets as described above. Immunogold
electron microscopy (EM) was performed as previously reported
(Crowther, 1991). Briefly, sarkosyl-insoluble samples were placed on
carbon-coated 400 mesh grid and labeled with anti-tau BR134 or AT8
antibodies and secondary antibodies linked to gold particles and nega-
tively stained with 1% potassium phosphotungstate. Micrographs were
recorded at a nominal magnification of 40,000 on a Philips EM208S
microscope.
Behavioral tests. Sensory function in 1- and 3-month-old P301S-htau
mice and age-matched C57BL/6S controls was evaluated in a blinded
fashion according to protocols commonly used to assess sensory dys-
function due to peripheral nerve injury (Wang et al., 2011; Gladman et
al., 2012). Mice were placed in a Plexiglas box with a wire mesh floor
(mechanical test) or a Plexiglas floor (thermal test), and habituated to the
chamber until they became calm. In the thermal sensitivity test, a stim-
ulus from an infrared light source (55°C; Ugo Basile) was directed
perpendicularly against the mouse left hindpaw. The period from appli-
cation of the stimulus to the withdrawal of the paw was recorded. If the
mousewas not responding to the stimuluswithin 15 s, the trial was ended
to avoid tissue damage. Mechanical threshold for paw withdrawal was
assessed using a dynamic plantar aesthesiometer (model 1601C; Life Sci-
ence Instruments). Probe was gently applied to the right hindpaw of the
animal and an increasing vertical force was applied until withdrawal of
the paw. The force at which the mouse withdrew its hindpaw was mea-
sured in grams by a force transducer. If the mouse did not respond to a
maximum force of 100 g, the trial was aborted. For each animal, five trials
were performed with a minimum of 10 min rest interval between each
recording. Significance was tested by one-way ANOVA followed by Bon-
ferroni post hoc adjustment.
Live imaging and mitochondrial transport. Dissociated DRG neurons
from P301S-htau and C57BL/6S mice at 3 and 5 months were grown on
glass-bottomed dishes for 40 h before incubation with 10 nM Mito-
Tracker Orange (Life Technologies) for 5 min at 37°C. Mitochondrial
dynamics along the axon were recorded with a 63 oil-immersion ob-
jective using a Leica AF7000 microscope with a Hamamatsu EM CCD
C9100 camera connected to Leica LAS AF software. The environment
was controlled with a heated stage set at 37°C (Heating Insert P; PeCon)
and aCO2 chamber set to 5%.Time lapse images ofmitochondrialmove-
ments were acquired every 5 s for 5 min (61 frames in total). Neuronal
cell bodieswere distinguished fromnon-neuronal cells by phase contrast.
To determine the directionality ofmitochondrialmovements, part of the
neuronal soma was included in the imaged field. Neurons from P301S-
htau mice were imaged blindly. To identify whether the recordings were
made from HT7ve and HT7ve neurons in the cultures from P301S-
htau mice, the x,y coordinates for each imaged cell were saved with LAS
AF software. After recording, cells were fixed with 4% PFA, stained with
the HT7 antibody, and the x,y coordinates of each previously imaged
neuron were recalled under themicroscope using the Leica software. For
dissociated DRG cultures from 3-month-old mice, 11 axons from four
independent culture preparations were imaged, yielding a total of 251,
283, and 212 mitochondria for C57BL/6S, P301S-htau HT7ve, and
HT7ve neurons, respectively. For animals at 5 months, 20 axons from
six independent culture preparationswere imaged, yielding a total of 456,
443, and 418 mitochondria for C57BL/6S, HT7ve or HT7ve neurons,
respectively. QuickTime movies and kymographs of time-lapse image
series were obtained with MetaMorph software (version 7; Molecular
Devices) and directionality of movement, distance, time traveled, and
average speed were determined. Mitochondria were classified as station-
ary if they did not move 2 m during the entire recording period
(Calkins and Reddy, 2011). For each age, the proportion of stationary
and moving mitochondria and the average speed were calculated by
pooling the mitochondria from all the imaged axons according to their
directionality. Normality of the data was estimated by both Kolmogorov–
Smirnoff normality test and D’Agostino–Pearson omnibus normality
test. For each imaged axon, the number of stationary, anterograde, and
retrograde moving mitochondria was calculated. Datasets for transport
were normally distributed so the significance of the differences in the
mitochondrial movements in C57BL/6S, P301S-htau HT7ve, and
P301S-htau HT7ve neurons from 3- and 5 month-old mice was tested
by two-way ANOVA followed by Bonferroni post hoc adjustment. Since
average velocity datasets were not normally distributed, data are pre-
sented as cumulative frequency distribution and the significance of the
differences was determined using the Kruskal–Wallis test (for three
groups) or Mann–Whitney test (for two groups; Falzone et al., 2009).
Statistics. Data were analyzed using GraphPad Prism version 5, IBM
SPSS version 21, orMetaMorph version 7 software.Where data followed
a normal distribution, one- or two-way ANOVA where appropriate was
followed by Bonferroni post hoc adjustment. For data that did not follow
a normal distribution, the Mann–Whitney or Kruskal–Wallis nonpara-
metric tests were applied where data from two or three groups, respec-
tively, were compared. Details of statistical tests and exact p values are
given in the figure legends. The symbols * or #, ** or ##, *** or ### denote
p values 0.05, 0.01, and 0.001 respectively.
Results
DRG neurons from P301S-htau mice contain insoluble
tau aggregates
Transgenic P301S-htau mice expressing human mutant tau under
the Thy1.2 promoter show extensive development of hyperphos-
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phorylated tau and filamentous tau aggregates (neurofibrillary tan-
gles, NFT) in brain and spinal cord at 5 months of age (Allen et al.,
2002). To establish whether DRG neurons from these mice express
transgenic P301S-htau, sections from the fourth lumbar ganglion
(L4) of 5-month-old mice were immunolabeled for the presence of
humantau(HT7antibody)andhyperphosphorylated tau (antibody
AT8). Immunofluorescent imaging showed that several DRG neu-
rons stained positively for human tau (Fig. 1A,a), including hyper-
phosphorylated tau (Fig. 1A,c). Some AT8ve neurons showed
cytoplasmic ring or crescent-like structures typical of NFTs (Fig.
1A,e).Theoccurrenceofhyperphosphorylated tau in lumbaraswell
as cervical and thoracic DRGs from 5-month-old transgenic mice
was further confirmed by immunolabeling with the phospho-tau
antibodies AT8 and AT180 (data not shown). There was no specific
labeling with any of the anti-phospho-tau antibodies in non-
neuronal cells, or in DRG neurons from age-matched C57BL/6S
controls (Fig. 1A,b,d).
The expressionof transgenicP301S-htauwas also investigatedby
immunoblotting using an anti-tau antibody that recognizes both
human andmurine tau isoforms. To resolve the individual isoforms
of tau, the samples were dephosphorylated with alkaline phospha-
tase (AP). A prominent bandof50 kDa (Fig. 1B) corresponding
to the transgenic human P301S tau aligned with a band from spinal
cord (SC) of P301S-htau mice, and with the 0N4R recombinant
Figure 1. DRG neurons in P301S-htaumice contain hyperphosphorylated tau, NFTs, and an associatedmechanosensory deficit. A, Sections (12m) from DRGs of 5-month-old P301S-htau and
C57BL/6S control mice were stained with anti-htau (HT7; a and b) or anti-phospho-tau (AT8; c– e) and visualized by fluorescence microscopy. The detail (e) shows typical ring and crescent-like
shapes formedbypathological htau. Scale bars:A,a–d, 200m;A,e, 50m.B, Perchloric acid-solubleprotein extracts fromP301S-htauDRGand spinal cord (SC) separatedbySDS-PAGEalongside
a SC extract from a control animal. Half of each sample was treated with alkaline phosphatase (AP). Blots were probed with anti-total tau antibody (Dako); white arrows: dephosphorylated
P301S-htau aligned with recombinant 0N4R htau band; *, murine tau isoforms. C, Hyperphosphorylation at pS202/pT205 detected with AT8 in perchloric acid-soluble tau extracts. D, Sarkosyl-
insoluble tauprepared fromDRGs from5-month-oldP301S-htauor controlmiceandaP301S-htaumousebrainprobedwithAT8.No insoluble tau is present in the control samplewhile a64kDaband
(arrow) is present in DRG and brain of P301S htaumice. E, Immunogold EM of the sarkosyl-insoluble tau fromDRGs probedwith AT8 antibody shows the presence of tau filaments. Bkg, background
immunogold labeling. No filamentswere observed in extracts from controlmice. Scale bars: 100 nm. F, Sensory tests in P301S-htau and C57BL/6Smice at 1 and 3months of age showno alterations
in thermal sensitivity (left) but a significant change in mechanosensitivity, as shown by the pressure test (right), which is altered in 3-month-old P301S-htau mice [(mean	 SEM; n
 7–10;
one-way ANOVA ( p
 0.012) followed by Bonferroni post hoc adjustment p
 0.021 (P301S-1m/P301S-3m); p
 0.032 (P301S-3m/C57BL6-3m); p
 0.018 (P301S-3m/C57BL6-1m)].
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isoform of human tau. This band was absent in spinal cord extracts
from C57BL/6S controls, where only three bands corresponding to
the three endogenousmouse tau isoforms were clearly visible in the
AP-treated samples. The presence of hyperphosphorylated tau
was confirmedby immunoblottingwith theAT8antibody (Fig. 1C).
Two closely spaced bands of64 kDa, possibly representing differ-
ent levels of tau phosphorylation, were present and aligned with
transgenic P301S-htau from spinal cord.
To determine whether DRGs from P301S-htau mice contain
filamentous insoluble tau, Sarkosyl-insoluble extracts were ana-
lyzed by immunoblotting with AT8 and by immunogold EM.
Immunoblotting showed a 64 kDa band in DRG and brain ex-
tracts from transgenic P301S-htau mice (Allen et al., 2002) but
not in DRGs from age-matched C57BL/6S mice (Fig. 1D). Fur-
thermore, immunogold EM of the Sarkosyl-insoluble extract re-
vealed the presence of AT8ve tau filaments resembling the
straight and narrow twisted filaments found in human tauopa-
thies and in the CNS of P301S-htaumice (Allen et al., 2002) (Fig.
1E). These data demonstrate that DRGs from P301S-htau mice
develop pathology thatmimics the features of tauopathy found in
CNS of P301S-htau mice and human disease.
Reducedmechanosensory response in P301S-htau mice
Because DRG neurons showed tau pathology, we asked whether
P301S-htau mice develop sensory deficits. Therefore, thermal
and mechanical sensitivities were studied in transgenic and con-
trol mice at 1 and 3 months of age to avoid the interference of
possible sensory deficits due to loss of motor functions. No defi-
cits were observed in the thermal acuity test in P301S-htau mice
compared with control mice (Fig. 1F, left), indicating that pain
and thermal sensations were intact. However, the pressure that
was required to elicit withdrawal of the hindpaw in 3-month-old
P301S-htau mice was significantly increased compared with age-
matched C57BL/6S and 1-month-old P301S-htau mice (Fig. 1F,
right; ANOVA p
 0.012, Bonferroni post hoc p
 0.018–0.032),
indicating a reduction in mechanosensory function. The likely
reason why the increase was relatively modest compared with
effects observed after sciatic nerve crush (Wang et al., 2011; Glad-
man et al., 2012) is that only a small proportion of the neurons
that respond to this stimulus express pathological forms of
P301S-htau, as shown next.
Dissociated adult DRG cultures from P301S-htau mice retain
tau pathology
To examine whether tau pathology found in the intact ganglia is
preserved in culture, DRG neurons were isolated from adult
P301S-htau mice at different ages and cultured for 2 DIV. In
neurons from 2-week-oldmice, P301S-htauwasmainly localized
in the soma and only a few neurons showed human tau (HT7)
labeling in their processes (Fig. 2A). However, in neurons from1-
to 5 month-old mice, HT7 labeling was found in the processes as
well as in the soma. In some neurons from 5-month-old P301S-
htaumice, a patchy pattern of labeling was observed in the axons.
HT7 labeling always colocalized with III tubulinve labeling,
confirming the neuronal expression of the transgene, as noted
previously by Thy1.2 GFP mice (Bradman et al., 2011; Fig. 2A).
The percentage of neurons showing P301S-htau in culture in-
creased according to the age of the mouse from which the DRG
were taken, reaching a plateau in cultures from 3-month-old
mice (HT7/III tubulinve neurons: 6% at 2 weeks, 12% at 1
month, 18% at 3 months, and 17.8% at 5 months; Fig. 2B). No
labeling for human tau (HT7) was detected in neurons from
C57BL/6S mice, in keeping with the results shown in Figure 1.
To evaluate the presence of hyperphosphorylated tau, neu-
rons were immunolabeled with different phosphorylation-
dependent anti-tau antibodies. PHF-1 labeling was present in
5% of HT7ve neurons cultured from 1-month-old mice, in-
creasing to 10% in neurons cultured from 3- and 5-month-old
P301S-htau mice (Fig. 2C,D). PHF-1 labeling was homoge-
neously distributed throughout the neurons though in someneu-
rons PHF-1 labeling was found only in the soma. DRG neurons
from 5-month-old mice expressing PHF-1 comprised 55% of
the HT7ve neurons (Fig. 2D), demonstrating that this was not a
rare event.
AT8ve labeling (Fig. 2E) was rarely observed in P301S-htau
cultures from 1-month-old mice (Fig. 2E,F, 0.15% of III
tubulinve), increasing slightly in cultures from 3-month-old
mice (1.1%). However, in cultures from 5-month-old P301S-
htau mice, 10.6% of the neurons stained AT8ve, with both the
cell body and the processes showing strong labeling. In some
axons this labeling was patchy, supporting the data obtained with
HT7 and suggesting the formation of aggregates. Similar to
PHF-1 labeling, in cultures from 5-month-old mice, AT8ve
neurons comprised55% of HT7ve neurons (Fig. 2F).
Labeling by AT100 has been associated with the presence of
tau filaments in our P301S-htau mouse line (Allen et al., 2002;
Yoshida and Goedert, 2006; Delobel et al., 2008). No AT100 im-
munoreactivity was present in cultures from 1-month-old
P301S-htau mice and was rarely detected in cultures from
3-month-old P301S-htau mice (Fig. 2G,H; 0–0.3% AT100ve/
HT7ve neurons).However, 5.3%of the neurons from5-month-
old mice were AT100ve, comprising 32% of HT7ve neurons.
Patchy labeling patterns were often observed in the axons, indi-
cating tau aggregation.
To directly establish the presence of filaments, Sarkosyl-
insoluble tau was extracted from neurons prepared from
5-month-old P301S-htau mice after 2 DIV and analyzed by im-
munoblotting and immunogold EM. Figure 2J shows that cul-
turedDRGneurons from5-month-old P301S-htaumice, but not
aged-matched C57BL/6S control mice, contained a Sarkosyl-
insoluble tau band similar to that present in brains of 5-month-
old P301S-htau mice. AT8ve tau filaments that were also
decorated by the phosphorylation-independent anti-tau anti-
body BR134 were detected by immunogold EM in Sarkosyl-
insoluble cell extracts (Fig. 2J). Thus, cultured neurons from the
DRG of transgenic P301S-htau mice preserve the attributes of
pathological tau found in the intact DRG and the CNS.
To investigate the subtype of neurons that express human tau
(HT7ve), we stained the cultures with the Griffonia simplicifolia
isolectin IB4, which detects small-diameter nonpeptidergic heat-
sensitive nociceptors (Silverman and Kruger, 1988; Snider and
McMahon, 1998; Stucky and Lewin, 1999). HT7ve neurons
were uniformly negative for IB4 labeling (Fig. 2K ), consistent
with the presence of a mechanosensory deficit and the lack of
a temperature-sensing deficit observed in vivo, as shown in
Figure 1.
P301S-htau-expressing DRG neurons are stained by the
pathological conformation-specific MC1 antibody
To further demonstrate that P301S-htauve DRG neurons ex-
press a disease-related conformation of tau, we stained cultures
with the antibodyMC1, which detects a disease-specific tau con-
formation in human AD (Jicha et al., 1997; Weaver et al., 2000;
Jeganathan et al., 2008; Fig. 3). Cultured P301S-htauve neurons
from 4- to 5-month-old mice, but not those from 3-month-old
or younger mice, showed the pathological conformational
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Figure 2. Dissociated DRG neurons from P301S-htaumice at different ages develop progressive tau pathology. Dissociated DRG neurons were prepared from P301S-htaumice at 2 weeks and 1,
3, and 5months of age, cultured for 2 DIV, and immunolabeledwith the indicated anti-human tau (HT7) or anti-phospho-tau antibodies and anti-III tubulin antibody.A, Developmental profile of
HT7ve immunolabeling at 2weeks and 1, 3, and 5months. Noteweak labeling of axons in sample cultured at 2weeks and complex pattern of outgrowth in neurons cultured at 1, 3, and 5months.
B, Theproportionof cells expressingP301S-htau (HT7ve) out of the totalIII tubulinve neurons is shownasa functionofmouseage (mean	SEM,n
6; one-wayANOVA ( p
0.003) followed
by Bonferroni post hoc adjustment; p
 0.0086 (2w/3m); p
 0.0093 (2w/5m)). C, E,G, Dissociated DRG neurons cultured for 2 DIV fromP301S-htaumice aged 1, 3, and 5months, immunolabeled
with the phosphorylation-dependent anti-tau antibodies PHF-1, AT8, and AT100. Scale bar, 100m.D, F,H, Quantification of the proportion of PHF-1/AT8/AT100ve neurons out of the totalIII
tubulinve neurons (n
 6), or HT7ve neurons (n
 3–4).Mean	 SEM, one-wayANOVA followed by Bonferroni post hoc adjustment. F, AT8/III tubulin ANOVA p
 5.1 107; p
 0.0011
(1m/5m); p
 0.0017 (3m/5m); Student’s t test; AT8/HT7 p
 0.0002.H, AT100/III tubulin ANOVA p
 1.2 105, p
 0.016 (1m/5m), p
 0.017 (3m/5m); Student’s t test; AT100/HT7 p

0.0012. I, Sarkosyl-insoluble tau was extracted from dissociated DRG neuron cultures (2 DIV) from 5-month-old P301S-htau or C57BL/6S mice and analyzed by immunoblotting using the HT7
antibody. Brain extracts from the same mice were used as positive controls. Note that the samples were run on the same blot but to visualize both sets of bands, (Figure legend continues.)
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change detected byMC1 (Fig. 3A).MC1 reactivity occurredwhen
PHF-1, AT8, and AT100 antibodies already detected tau hyper-
phosphorylation. No MC1 reactivity was detected in C57BL/6S
control neurons. Thus, althoughMC1 is not a phospho-epitope-
specific antibody, our data agree with biochemical studies that
indicate that MC1 recognizes a conformation that depends on
there being prior phosphorylation at all three (PHF-1/AT8/
AT100) epitopes (Jeganathan et al., 2008). In neurons from
4-month-old P301S-htau mice cultured for 2.5 weeks, MC1
showed a patchy labeling suggestive of tau aggregation (Fig. 3B).
P301S-htau-expressing DRG neurons display aberrant
morphologies
We next examined axon regeneration of P301S-htauve DRG
neurons. Abnormal morphologies were observed in P301S-htau-
expressing (HT7ve) DRG neurons grown for 2 DIV from 1-, 3-,
and 5-month-old P301S-htau transgenic mice (Fig. 4), while the
growth of HT7ve neurons present in the same cultures was sim-
ilar to that of the nerve cells from age-matched C57BL/6S con-
trols. The abnormal patterns consisted of short neurites with
enlarged and amorphous growth cones, and thickened axonal
processes with increased branching and accumulation of tau at
the branch point (Fig. 4 A,B) as has been observed in neurons in
tauopathies. These changes were already evident in neurons from
1-month-old mice. Moreover, P301S-htau HT7ve neurons, in
particular those from 3- and 5-month-old P301S-htau mice,
showed disorganizedMTs. For example, at the leading edge of the
growth cone, MTs were not dynamically protruding towards the
finger-like filopodia, but were bent and looped (Fig. 4C). Such
structures are similar to those previously reported in resting
growth cones that have lost their direction of growth due to struc-
tural changes ofMTs (Conde andCa´ceres, 2009; Lowery andVan
Vactor, 2009), or in growth cones whose MTs have been overly
stabilized due to lack of tip proteins or treatment with taxol
(Gumy et al., 2013). Most interestingly, large axonal swellings
similar to the spheroids found in human tauopathies (Murrell et
al., 1999) were found along the axons, whereMTs stainedwith an
anti-III tubulin antibody seemed to have lost an ordered struc-
ture (Fig. 4D). A peculiar feature of dissociated DRG cultures
from 5-month-old P301S-htau mice was the presence of struc-
tures that were highly immunoreactive for phospho-tau (PHF-1,
AT8 or AT100) but which had reduced or absent III tubulin
immunoreactivity and nuclear DNA staining (Fig. 4E). In some
cases these structures were reminiscent of “ghost-like” tangles
found inAD,where tau labeling shows the shape of a neuronwith
very little or no III tubulin labeling and no nuclear staining
(Duyckaerts et al., 2009). To assess the impact of P301S-htau
expression on axon growth, we quantified the length of the lon-
gest axon per neuron, and the areas of the associated growth
cones. Axons from P301S-htau HT7ve neurons were signifi-
cantly shorter and displayed significantly larger growth cones
compared with HT7ve neurons from the same cultures or
C57BL/6S nerve cells (Fig. 4F). This effect was already evident in
cultures from 1-month-old mice, indicating that problems with
reorganization of theMTs necessary for regeneration after injury
(Gumy et al., 2013) may be an early response to the presence of
P301S-htau.
Mitochondrial trafficking is altered differently in P301S-
htau-expressing neurons at different ages
To test whether there were any changes in mitochondrial trans-
port in relation to the temporal development of tau pathology,
mitochondria were imaged in the axons of live DRG neurons (2
DIV) after labeling with MitoTracker Orange (Fig. 5A, right).
Recordings were blinded as to whether the neurons were HT7ve
or HT7ve. After recording, the HT7 status of the imaged neu-
rons was determined by immunofluorescence. Time-lapse re-
cordings were analyzed by kymography, typical profiles of which
are shown in Figure 5A). Quantification of stationary and antero-
gradely and retrogradely moving mitochondria showed that the
percentage of stationary andmotile mitochondria in P301S-htau
HT7ve neurons did not differ from that of C57BL/6S and
P301S-htau HT7-negative axons in DRG neurons from
3-month-old mice (Fig. 5B). The distance traveled by mitochon-
dria was also not altered in the three neuronal groups in cultures
from 3-month-old or 5 month-old mice, nor did we note any
systematic change in mitochondrial length between the three
groups such as that recently reported (Duboff et al., 2012). How-
ever, in neurons from 5-month-old animals the percentage of
stationary mitochondria was significantly increased by40% in
P301S-htau HT7ve neurons compared with HT7ve neurons,
while movement was significantly reduced by 50% in the an-
terograde direction and by 30% in the retrograde direction
compared with P301S-htau HT7ve and C57BL/6S groups, re-
spectively (Fig. 5B). Conversely, cumulative distribution analysis
of average velocities among the three groups showed that in
3-month-old P301S-htau HT7ve axons, mitochondria were
moving significantly faster in both directions compared with
C57BL/6S and P301S-htau HT7ve neurons, whereas similar av-
erage velocities were found in the three experimental groups
from 5-month-old mice (Fig. 5C), indicating that the remaining
motile mitochondria were pacing along the axon with a speed
comparable to controls. These data demonstrate that there are
two independent outcomes of mitochondrial transport in tau-
expressing DRG neurons: at early time points, when there are no
detectable tau aggregates, mitochondria move slightly faster than
in wild-type controls, whereas in neurons associated with fila-
mentous tau aggregates, there is a significant global loss of mito-
chondrial movement.
DRG cultures established from nonsymptomatic age develop
tau pathology in vitro
Cultured neurons fromDRGs would be most valuable for studying
the development of tau pathology if its progression could be repli-
cated in vitro. To examine whether neurons cultured from P301S-
htau DRGs at early stages, before detection of tau modification,
develop tau pathology, dissociated DRG cultures were established
from3-month-old P301S-htaumice and grown for8weeks. Cov-
erslips were removed every few days and stained for the presence of
AT8,HT7, andIII tubulin reactivities (Fig. 6A showsanexampleof
AT8ve neurons from 3-month-old mice after 52 DIV). Despite
startingoff asAT8ve cultures,within 2weeks10%of theHT7ve
neurons developedAT8ve labeling (Fig. 6B), whichwas initiated in
the somaand eventually spread through the axon.Thepercentage of
AT8ve neurons out of the HT7ve cohort increased with time in
4
(Figure legend continued.) the image on the left was exposed for 10min whereas the image
on the rightwasexposed for 1min. J, Sarkosyl-insoluble tauwasextracted fromdissociatedDRG
neuron cultures (2 DIV) from 5-month-old mice and analyzed by immunogold EM with the
phosphorylation-independent andphosphorylation-dependent anti-tau antibodies BR134 and
AT8, respectively. Tau filaments from the cultured cells appear as straight or narrow twisted
filaments and are similar to those found in DRG tissue from 5-month-old mice shown in Figure
1. Scale bars: 100nm.K, DRGneurons from3-month-oldP301S-htaumicewere cultured for 2d,
fixed, and stainedwith IB4-FITC (green) andHT7 (red), and imagedby fluorescencemicroscopy.
Note lack of overlap between the two probes.
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Figure 3. MC1 reactivity develops in culture at a late stage of pathology. A, DRG neurons cultured for 2 DIV from 1-, 2-, 3-, and 5-month-old P301S-htau or 5-month-old C57BL/6S mice were
stained with antibody MC1 (green), HT7 (red); merged images also show labeling forIII tubulin (white). B, DRG neurons from 4-month-old mice stained with MC1 (green). Note MC1-positive
aggregates in the axons and cell bodies, Scale bars: 50m.
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culture, reaching50%ofHT7ve neurons after 8 weeks (Fig. 6B),
similar to the 50%value foundwhenneuronswere directly cultured
from the DRGs of 5-month-old P301S-htau mice (Fig. 2). The pat-
tern of AT8ve labeling in the cell body ranged from being uniform
to being patchy, aggregated, or forming ring-like structures (Fig.
6C), similar toprofilesobserved inhistological sectionsofDRGfrom
5-month-old P301S-htau mice (Fig. 1A). These data indicate that
the development of pathological formsof tau is recapitulated in vitro
inDRGneurons fromP301S-htaumice, and thusprogressionof tau
pathology can be followed in vitro from early stages.
We also examined whether we could maintain long-term cul-
tures of neurons from 5-month-old mice, when DRG neurons
Figure 4. Cultured P301S-htau-expressing DRG neurons display early morphological abnormalities. Low-density dissociated DRG cultures were grown for 2 DIV, fixed, and immunolabeled with
HT7 andanti-III tubulin antibodies.A–C, Enlarged and stuntedgrowth coneswith splayedMTs and thickened, looped, andbent axons are present in neurons from1-month-old P301S-htaumouse
but not C57BL/6S control. D, A spheroid bulge in an axon from a 3-month-old mouse. Spheroids are often found in human tauopathy brains. E, Residual tangles of aggregated tau in degenerating
cellswith little or noIII tubulin (red) or nuclear stain (blue) in cultures from5-month-oldmice. Arrows point to typical tau deposits that stain for PHF-1, AT8, or AT100 (green).Merged imageswere
capturedwith a fluorescencemicroscope using a 20 objective. Scale bars:A–D, 50m; E, 20m. F, Quantification of axon length and growth cone area in cultures from 1-, 3-, and 5-month-old
mice show reduction in axon length and an increase in growth cone area in DRGswith P301S-htau comparedwith DRGwithout htau (P301S-HT7ve) or fromC57BL/6S controlmice (mean	 SEM,
n
 3 for C57BL/6S cultures andn
 4 for P301S-htau cultures, two-wayANOVA followedbyBonferroni post hoc adjustment). (Axon length: ANOVAC57BL/6S/P301S-HT7ve/P301S-HT7ve p

4.5 105, 1m/3m/5m p
 1 105, Interactions p
 0.0368; p
 0.0002 (1m C57BL/6S/ P301S-HT7ve), p
 1.3 105 (1m P301S-HT7ve/P301S-HT7ve), p
 0.0025 (3m
C57BL/6S/ P301S-HT7ve), p
 0.0005 (3m P301S-HT7ve/P301S-HT7ve); p
 0.0003 (5m C57BL/6S/ P301S-HT7ve), p
 1.2 105 (5m P301S-HT7ve/P301S-HT7ve); Growth cone
area: ANOVA C57BL/6S/P301S-HT7ve/P301S-HT7ve p
 0.0256, 1m/3m/5m p
 5 104, p
 0.0009 (1m C57BL/6S/P301S-HT7ve), p
 0.0008 (1m P301S-HT7ve/P301S-HT7ve),
p 
 0.0002 (3m C57BL/6S/P301S-HT7ve), p 
 2.5  105 (3m P301S-HT7ve/P301S-HT7ve); p 
 0.0018 (5m C57BL/6S/ P301S-HT7ve), p 
 0.0004 (5m
P301S-HT7ve/P301S-HT7ve).
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Figure 5. Mitochondrial movement is differentially altered in DRG neurons from P301S-htaumice. DRG neurons from 3-month-old or 5 month-old P301S-htau or C57BL/6Smice were cultured
for 40h, then incubated inmediumcontaining10nMMitoTrackerOrange for 5minat37°C just before imaging. P301S-htauve neuronswere relocatedafter theexperimentby immunolabelingwith
HT7 antibody.A, Representative time-lapse image series (1 frame every 5 s for 5min) of C57BL/6S, P301S-htau HT7ve, and P301S-htau HT7ve neurons from3- and 5-month-oldmice converted
into kymographs. Vertical tracks represent stationarymitochondriawhile oblique tracks depict themoving organelles. A typical snapshot ofmitochondria in a P301S-htauHT7ve andHT7ve axon
is shown to the right of the kymographs. Note that the density and shapes of polarized mitochondria in the axons are similar between the HT7ve and HT7ve neurons. B, Quantification of the
proportion of stationary and moving mitochondria in the anterograde and retrograde directions (mean	 SEM, n
 11 axons from 3-month-old mice, n
 20 axons from 5-month-old mice;
two-way ANOVA with Bonferroni post hoc adjustment; Stationary: ANOVA p
 5 107; p
 0.0006 (5m P301S-HT7ve/5m P301S-HT7ve), p
 5 107; (5m P301S-HT7ve/5m
C57BL/6S), p
 4.7 105 (5m P301S-HT7ve/3m C57BL/6S), p
 0.1 107 ( (5m P301S-HT7ve/3m P301S-HT7ve), p
 5 107 (5m P301S-HT7ve/3m P301S-HT7ve), p

0.0099 (5mP301S-HT7ve/3mP301S-HT7ve); Anterograde: ANOVAp
2106;p
0.0003 (5mP301S-HT7ve/5mP301S-HT7ve),p
2.1105 (5mP301S-HT7ve/5mC57BL/6S),
p
 8 106 (5m P301S-HT7ve/3m C57BL/6S), p
 0.0333 (5m P301S-HT7ve/3m P301S-HT7ve); Retrograde: ANOVA p
 0.0041, p
 0.0325 (5m P301S-HT7ve/5m C57BL/6S), p

0.0159 (5m P301S-HT7ve/3m C57BL/6S), p
 0.0457. C, Analysis of cumulative anterograde and retrograde average velocity distributions. Cumulative distribution statistics: Anterograde: p

0.0592 (3mC57BL/6S/3mP301S-HT7ve), p
 2.5 105 (3mC57BL/6S/3mP301S-HT7ve), p
 0.0221 (3mP301S-HT7ve/3mP301S-HT7ve); Retrograde: p
 0.7128 (3mC57BL/6S/3m
P301S-HT7ve), p
 1.12 105 (3m C57BL/6S/3m P301S-HT7ve), p
 0.0008 (3m P301S-HT7ve/3m P301S-HT7ve); Average speed in both directions was increased in HT7ve neurons
from 3-month-old mice compared with HT7ve neurons or C57BL/6S controls, but not in cultures from 5-month-old animals. The average speed of mitochondria in P301S-htau HT7ve neurons
from 3-month-old mice was also significantly greater than that from 5-month-old mice; p
 0.0199 (3m/5m P301S-HT7ve Anterograde), p
 0.0418 (3m/5m P301S-HT7ve Retrograde).
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show tau abnormalities, thereby extending their lifetime to an age
equivalent to that of 7-month-old mice, which is beyond the age
the animals are permitted to survive. Over 2 months in culture
the number of AT8ve neurons significantly decreased relative
to the total number HT7ve neurons (p 
 0.0173), indicating
that neurons with htau hyperphosphorylated at this site die pref-
erentially. For AT100ve neurons, the results weremore variable;
in two experiments there was a similar extent of loss of neurons as
that found for AT8ve neurons (p 
 0.0413), but in two other
experiments the decrease over time did not reach significance,
maybe because some neurons were still developing the AT100
epitope while others were dying. The reduction in the percentage
of total HT7ve neurons relative to that of III tubve popula-
tion was also not significant (p 
 0.052–0.062), most likely
because of the relatively small contribution made by AT8/
AT100ve neurons to the total neuron population present. These
data indicate that long-term cultures from 5-month-old animals
may be useful to study the mechanisms of tau-induced cell death
mainly related to the decrease in the population of neurons that
are stained by AT8.
Long-term treatment of DRG cultures with the O-GlcNAcase
inhibitor SEG28019 reduces PHF-1ve labeling
To investigate the feasibility of using P301S-htauve DRG neu-
rons as a platform for testing drugs that may ameliorate tau pa-
thology, we treated the cultures with SEG28019, a novel inhibitor
of O-GlcNAcase, the enzyme that removes O-GlcNAcylated
groups from serines and threonines (Hart et al., 2011). Inhibi-
tion of this enzyme has been shown to increase protein
O-GlcNAcylation in lieu of phosphorylation (Hart et al., 2011).
Tau is normally modified by O-GlcNAc at some of the same sites
that are hyperphosphorylated in AD and other tauopathies, and
the amount of tau O-GlcNAcylation is consistently reduced in
AD brains, leading to the idea that O-GlcNAc inhibitors might
prevent tau phosphorylation at specific sites and ameliorate tau
pathology (Lefebvre et al., 2003; Liu et al., 2004).One epitope that
is differentially O-GlcNAcylated in tau is Ser396, the motif rec-
ognized by the antibody PHF-1 (Yuzwa et al., 2008, 2012; Yu et
al., 2012). We added 10 M SEG28019 to the growth medium of
DRG neurons cultured from 3-month-old P301S-htaumice over
7weeks and testedwhether therewere any changes in steady-state
Figure 6. DRG neurons from P301S-htaumice develop tau pathology during long-term culture in vitro.A, Profile of a typical long-lived AT8ve/HT7ve DRG neuron cultured from 3-month-old
mice after 8 weeks in vitro. B, DRG neurons cultured from 3-month-old P301S-htau mice were fixed at the days indicated, and the proportion of HT7ve neurons out of the totalIII tubulinve
neuron population (F), or the proportion of AT8ve neurons out of the total HT7ve population (E) was quantified. Each point is themean value of replicates from one culture of threemice. The
lines depict a linear regression and the dashed lines show the 95% confidence intervals. For ratio of HT7ve/III tubve: R 2
 0.08, F test for slope being different from zero, p
 0.32 (not
significant); for AT8/HT7ve: R 2
 0.71, F test for slope being different from zero, p
 0.0002. C, Detail of three adjacent neurons stained with AT8 (red) andIII tubulin (white) after 8 weeks,
showing typical profiles of pathological tau: *, AT8ve large cytoplasmic aggregates; **, AT8ve small cytoplasmic aggregates; ***, AT8ve cytoplasmic perinuclear crescent. D, E, DRG neurons
from 5-month-old P301S-htau mice cultured for 73 d. Left, Quantification of the proportion of AT8ve (D) and AT100ve (E) neurons out of the total HT7ve population (E), and the proportion
ofHT7ve neurons out of the totalIII tubulinve neuronpopulation (F). Eachpoint shows themeanvalue	 SEM independent cultures from three to fourmice except for the result at 73d,which
shows the average	 range from twomice. Points without error bars are because the errors were smaller than the size of the point. The lines depict a linear regression through the total cohort of
raw values for each condition (17 data points). For ratio of AT8/HT7ve: R 2
 0.36, F test for slope being different from zero, p
 0.0173; For overall ratio of AT100/HT7ve: R 2
 0.19, F test for
slope being different from zero, p
 0.0993; HT7ve/III tubve in samples stained for AT8, p
 0.052; AT100, p
 0.062 (not significant).
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tau phosphorylation at the PHF-1 epitope. Figure 7A shows that
total O-GlcNAcylation was significantly higher in SEG28019-
treated neurons compared with untreated cohorts. When the in-
tensity of PHF-1 immunoreactivity was measured in individual
HT7ve neurons, a significant reduction in PHF-1 labeling rela-
tive to HT7 labeling intensity was evident in the SEG28019-
treated cohort compared with the untreated control (Fig. 7B).
This change was subtle in that there was no significant difference
between the two treatment groups when total PHF-1 immuno-
fluorescence was averaged; the difference was only revealed when
the intensity of PHF-1 labeling was normalized to that of anti-
human tau HT7 labeling intensity, indicating that some, but not
all, of the neurons are affected by the drug at any one time. Thus,
using DRG neurons from P301S-htau mice, we have teased out
small differential effects of the OGA inhibitor SEG28019 after
long-term treatment, similar to the period of treatment others
have applied in vivo. Although a subtle yet significant change was
observed for the SEG28019 in DRG neurons, this may be suffi-
cient to elicit a change in disease pathology and hence explain the
observed benefits of O-GlcNAcase inhibition in tauopathy mod-
els (Yuzwa et al., 2012).
Discussion
This study shows that in transgenic P301S-htau mice, htauve
DRG neurons develop tau pathology with similar characteristics
to those found in human tauopathies. This pathology was asso-
ciated with some evidence of reduced sensory function. More-
over, htauve DRG neurons cultured from adult P301S-htau
mice of different ages displayed the same developmental pattern
of tau pathology as DRG and CNS neurons in vivo. Furthermore,
functionally, axonal transport of mitochondria was differentially
altered in the htauve neurons depending on whether tau was
aggregated or just hyperphosphorylated. Remarkably, long-term
cultures of DRG neurons from presymptomatic P301S-htau
transgenic mice recapitulated aspects of progressive tau pathol-
ogy as theymatured, as indicated by increasing AT8 labeling over
2 months starting with neurons from 3-month-old mice. Fur-
thermore, there was preferential neuronal death of AT8ve neu-
rons and some AT100ve neurons over 2 months when starting
with neurons from advanced stage disease (5-month-old mice).
Thus, these cultures provide a unique system where tau filament
formation is self-generating without a requirement for special
Figure 7. The O-GlcNAcase inhibitor SEG28019 reduces PHF-1 immunoreactivity in DRG neurons.A, DRG neuronswere cultured from5-month-old P301S-htaumice for 6 d afterwhich SEG28019
(SEG; 10M)was added for 22 h. Cells were fixed and stained for the presence of O-GlcNAcmodification using the RL2 antibody (green) and anti-III tubulin (white) and visualized by fluorescence
microscopy. Bar graph shows average cytoplasmic intensity of RL2 labeling from two independent cultures. Mean	 SEM, NoSEG28019, n
 91 neurons;SEG28019, n
 151 neurons. ANOVA
p
 1.48 1015; t test, p
 2.16 107. Scale bar, 20m.B, DRGneuronswere cultured from twodifferent litters of 3-month-old P301S-htaumice. SEG28019 (10M)was added at day two
and freshly added two times a week over 7 weeks. Cultures were fixed and stained with anti-phospho tau antibody PHF-1 and for human tau (HT7) and visualized by fluorescence microscopy. The
intensity of PH-1 labeling was normalized to the intensity of HT7 labeling to offset fluctuations due to different amounts of htau expression. The graphs show the ratios plotted as fractional
cumulative distribution plots for three independent cultures from litter a (left and middle) and litter b (right). Note that there is a higher fraction of neurons with lower PHF-1/HT7 intensity in the
SEG28019-treated cultures compared with the nontreated cultures. Data were analyzed using a nonparametric Mann–Whitney test. Left plot, No SEG28019 n
 89,SEG28019 n
 59, p

0.0029. Middle plot, No SEG28019 n
 91,SEG28019 n
 91, p
 0.0013. Right plot, No SEG28019 n
 150, SEG28019 n
 146, p
 0.0012.
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manipulations or seeding of exogenous tau, differently from cul-
tures recently described (Vogelsberg-Ragaglia et al., 2000; Sato et
al., 2002; Ferrari et al., 2003; Pe´rez et al., 2003; Alonso Adel et al.,
2006; Iliev et al., 2006; Wang et al., 2007; Guo and Lee, 2011,
2013), and neuronal death associatedwith hyperphosphorylated/
conformationally altered htau occurs spontaneously as we
showed in the cortex of the same transgenic line in vivo (Hamp-
ton et al., 2010). Our results also differ from those described in a
wild-type htau transgenic mouse, where no increase in hyper-
phosphorylated or aggregated tau in DRG neurons was observed
(Nuydens et al., 2002).
Although sensory deficits are not hallmarks of human tauopa-
thies, there may be prevalent tau pathology in the PNS, as indi-
cated by studies where tau pathology was found in lumbar DRG
neurons of several PSP patients (Nishimura et al., 1993) and in
upper cervical ganglia of AD patients (Kawasaki et al., 1987). To
investigate the consequences of tau pathology in the DRGs, we
testedwhether expression of P301S-htauwas associatedwith sen-
sory deficit, studying 1- and 3-month-old mice to avoid compli-
cations due to themotor neuron death andmotor phenotype that
occurs at 5 months of age. At 1 month, when there was little
AT8ve labeling, no sensory deficits were detected.However, by 3
months of age, when 50% of the HT7ve neurons were AT8ve,
thermal nociceptive thresholds were normal, but there was a sig-
nificant loss of mechanosensation. Since there was little detect-
able AT100 labeling at 3 months, which reflects tau filament
formation in the P301S-htau mice (Allen et al., 2002), these re-
sults indicate that more advanced pathology was not necessary
for revealing sensory deficits, as shown previously in this mouse
model (Scattoni et al., 2010). Moreover, the late appearance of
MC1ve-positive neurons suggests that tau hyperphosphoryla-
tion at AT8 and PHF-1 epitopes occurs in DRG neurons before
this disease-linked conformational alteration is detectable. In
keeping with the observation of a sensory-specific impairment,
we show that P301S-htauve neurons are IB4ve, whereas IB4ve
neurons are mainly small-diameter nonpeptidergic heat-sensitive
nociceptors (Silverman andKruger, 1988; Snider andMcMahon,
1998; Stucky and Lewin, 1999).Whether the P301S-htauve neu-
rons belong to one class or modality will require closer scrutiny.
Neurons expressing P301S-htau showed several aberrant pat-
terns of axonal outgrowth reminiscent of pathological forms
found in human tauopathies. Most notably, spheroids formed
within axons, and the MTs were splayed and bent in the growth
cones, indicating the predominance of static over dynamic MTs,
similar to the patterns we (data not shown) and others (Letour-
neau andRessler, 1984) observedwhen low (10–100 nM) concen-
trations of taxol were added to enhanceMT stability.Where axon
growth occurred, the pattern of growth was interrupted by kinks
and bends, and the overall axon length was markedly reduced, as
previously observed in retinal explants from P301S-htau mice
(Gasparini et al., 2011). Also similar to human tauopathies, some
degenerating neurons cultured from5-month-oldmice lostmost
of their MT labeling and in some cases nuclear staining was also
missing, leaving AT8/AT00ve deposits possibly reminiscent of
ghost-like tangles. To our knowledge, this has not been previ-
ously reported in cultured neurons. Hence, reorganization of the
cytoskeleton to provide dynamic MTs necessary for proper re-
generative outgrowth appears to be deficient in the transgenic
neurons. Some of the aberrant patterns could have been due to
expression of excess tau rather than mutant tau (Nuydens et al.,
2002), but these changes were not because of overexpression per
se as we did not observe them in DRG neurons cultured from
5-month-old Thy1.2-YFP transgenic mice, where YFP is overex-
pressed (data not shown). In keeping with this notion, reduced
outgrowth length was already pronounced inDRGneurons from
1-month-old P301S-htau mice, a stage that is before consistent
tau phosphorylation as detected by AT8 or AT100. Whether this
deficit is linked to phosphorylation at the PHF-1 epitope,which is
already present in 50% of the HT7ve neurons at 1 month of
age, will require further study.
To test for functional tau-related deficits at the cellular level,
we studied themovement of polarizedmitochondria in the axons
ofDRGneurons grown for 2DIV.Unlike reports of axonal trans-
port in other htau transgenic mice (Spittaels et al., 1999; Leroy et
al., 2007; Ittner et al., 2008), the number or shape of mitochon-
dria inDRG axons did not differ between P301S-htauve, P301S-
htauve, and C57BL/6S neurons. Hence, delivery of polarized
mitochondria to axons that are 100 m long was not limited,
norwas there any evidence for the accumulation ofmitochondria
in cell bodies, as found in early differentiated N2A cells or in
primary neurons (Ebneth et al., 1998; Stamer et al., 2002). In-
stead, mitochondrial movement displayed two distinct patterns:
in HT7ve neurons from 5-month-old mice, there was an in-
crease of 50% in the proportion of stationary mitochondria
compared with HT7ve neurons from the same culture or to
control neurons. This occurred with a concomitant reduction in
both anterograde and retrograde moving fractions. There were
no changes in these parameters in neurons from 3-month-old
mice. Interestingly, in vivo studies in the optic nerve found alter-
ations in anterograde and retrograde transport of cholera toxin B
at both 3 and 5 months (Bull et al., 2012). It is likely that cholera
toxin B andmitochondria use different mechanisms of transport
(e.g., endosomal vs Milton/Miro; Vershinin et al., 2007; Saxton
and Hollenbeck, 2012), different supply of ATP (Zala et al.,
2013), and/or that the timescale of the experiments and travel
distance reveal different aspects of axonal transport pathology.
Only in P301S-htau HT7ve DRG axons from 3-month-old, but
not 5-month-oldmice, a proportion ofmitochondriamoved sig-
nificantly faster compared with C57BL/6S and P301S-tau
HT7ve neurons. There were no differences in the run length
between the three groups at any age, so the increased velocity was
an intrinsic feature. The reasons underlying mitochondria in-
creased velocity in 3-month-old DRG axons remain unclear. A
related phenomenon was recently reported for mitochondria in
the tibial nerve of P301L tau knockin mice with no tau aggrega-
tion (Gilley et al., 2011), where an increased fraction of antero-
gradely moving mitochondria was found in young mice,
switching to a decreased fraction in old mice. Thus, opposing
switches in the rate or fraction of moving mitochondria, are not
necessarily related to differences between intact nerves and cul-
tured axons. Another reason for the slightly higher motility of
mitochondria in axons from our 3-month-oldmicemay relate to
altered axonalmetabolic demands (Miller and Sheetz, 2004).Our
preliminary evidence suggests that most mitochondria are polar-
ized in the axons of HT7ve neurons regardless of age, but it is
possible that the metabolic demands of the axon change depend-
ing on the phosphorylation status of P301S-htau, such that ini-
tially the cell increases anterograde mitochondrial movement to
provide higher energetic supply, but with the progression of tau
pathology, this regulatory step fails.
To demonstrate the usefulness of DRG neurons as a platform
for drug testing, we used SEG28019, a novel inhibitor of
O-GlcNAcase (Hart et al., 2011; Horne et al., 2011). Inhibition of
O-GlcNAcase is predicted to increase tau O-GlcNAcylation in-
hibiting its detrimental phosphorylation in specific sites such
as the epitope of PHF-1 antibody Ser 396. However, recent
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studies (Yuzwa et al., 2008, 2012; Yu et al., 2012) could not
detect a significant reduction in tau phosphorylation follow-
ing O-GlcNAcase inhibition with Thiamet G leading to the con-
clusion that its effect was possibly not mediated via tau
phosphorylation. Here we show that SEG28019 reduced tau
phosphorylation at the PHF-1 epitope, while preliminary results
showed no change in AT8 phosphorylation or labeling of the
MC1 epitope. These observations show how specific changes can
be dissected out in our model with developing tau pathology.
In conclusion, we show a highly reproducible and versatile
neuronal model where tau hyperphosphorylation and aggrega-
tion develop without additional manipulation. This model will
be useful for investigating mechanisms of tau-related neuronal
dysfunction, and to test new therapies for tauopathies.
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